Cargando…

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures

INTRODUCTION: Low density lipoprotein (LDL-C) apheresis is a last treatment option for hypercholesterolemic patientsresistant to conservative lipid-lowering therapy. In a retrospective analysis of 8,533 heparin-induced extra-corporeal LDL precipitation apheresis treatments (HELP), we evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buuren, Frank van, Kreickmann, Sven, Horstkotte, Dieter, Kottmann, Tanja, Mellwig, Klaus Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374104/ https://www.ncbi.nlm.nih.gov/pubmed/22528135 http://dx.doi.org/10.1007/s11789-012-0048-4

Ejemplares similares

Lipid apheresis: oxidative stress, rheology, and vasodilatation
por: Mellwig, K.-P., et al.
Publicado: (2012)

Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention?
por: Mellwig, Klaus-Peter, et al.
Publicado: (2017)

Biomolecular Evidence of Silk from 8,500 Years Ago
por: Gong, Yuxuan, et al.
Publicado: (2016)

Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease
por: van Buuren, Frank, et al.
Publicado: (2017)

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia
por: Zanetti, Michela, et al.
Publicado: (2014)

Adverse events associated with apheresis procedures: Incidence and relative frequency
por: Philip, Joseph, et al.
Publicado: (2013)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
por: Bulut, Muhammet, et al.
Publicado: (2020)

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
por: Varga, Viktória E., et al.
Publicado: (2016)

Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia
por: Lischka, Julia, et al.
Publicado: (2022)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Adjudication of a Contract for the Supply of 8500 Tonnes of Heavy Fuel Oil
Publicado: (1978)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

Proposal for the award of a contract for the supply of approximately 8500 tonnes of heavy fuel oil
Publicado: (1984)

Proposal for the award of a contract for the supply of approximately 8500 tonnes of heavy fuel oil
Publicado: (1985)

Increasing summer rainfall in arid eastern-Central Asia over the past 8500 years
por: Hong, Bing, et al.
Publicado: (2014)

Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia
por: Al-Dughaishi, Tamima, et al.
Publicado: (2015)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia
por: Dlouha, Dana, et al.
Publicado: (2023)

Need for plateletpheresis procedure with voluntary regular apheresis donors: An experience
por: Shah, Ripal J., et al.
Publicado: (2018)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Marked Regression of Left Ventricular Hypertrophy after Outflow Desobliteration in HOCM
por: Dimitriadis, Zisis, et al.
Publicado: (2012)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Polyzwitterionic Coating of Porous Adsorbents for Therapeutic Apheresis
por: Semak, Vladislav, et al.
Publicado: (2022)

Apheresis: What Should a Clinician Know?
por: Parhofer, Klaus G.
Publicado: (2023)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Reimbursement for therapeutic apheresis devices and procedures for using the healthcare insurance system in Japan
por: Kusaoi, Makio, et al.
Publicado: (2020)

Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion
por: Duchez, Anne-Claire, et al.
Publicado: (2023)

Apheresis in Neurological Disorders
por: Dorst, Johannes
Publicado: (2020)

Apheresis and Covid-19
por: Griveas, Ioannis
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q0vsv7gcbl81m79j871vdg7tsj